



Curriculum Vitae

Personal information **Henrik Dahllöf**

Work experience

1. Employer: Medical Products Agency
 - Start date: 042021
 - End date:
 - Position: Senior Clinical Assessor
 - Activities:
 - Country: Sweden
2. Employer: Medical Products Agency
 - Start date: 092019
 - End date: 032021
 - Position: Senior Preclinical Assessor
 - Activities:
 - Country: Sweden
3. Employer: Medical Products Agency
 - Start date: 052015
 - End date: 082019
 - Position: Preclinical Assessor
 - Activities: • Scientific assessment of pharmacology, pharmacokinetics and toxicology data in European clinical trials and marketing authorization applications of medical drugs within all disease areas. • Prepare written central scientific advice (European Medicines Agency) and oral national scientific advice (Swedish Medical Products Agency).
 - Country: Sweden
4. Employer: Bayer Healthcare
 - Start date: 012013
 - End date: 042015
 - Position: Lab Head & Scientific Manager
 - Activities: Scientific and project leadership across the drug discovery process for small molecules and biologics (mAbs) within neuroscience area focusing on inflammation and pain.
 - Country: Germany
5. Employer: AstraZeneca R&D
 - Start date: 102001
 - End date: 122012
 - Position: Senior Research Scientist
 - Activities: Pharmacologist and Project Lead in drug discovery within neuroscience area focusing on chronic pain and inflammation
 - Country: Sweden

Education and training

1. Subject: Department of Physiology & Pharmacology
 - Start date: 1997
 - End date: 012001
 - Qualification: PhD _ Medical Science (pharmacology)
 - Organisation: Experimental Pharmacology Karolinska Institutet, Stockholm
 - Country: Sweden
2. Subject:
 - Start date:
 - End date: 1996
 - Qualification: Master's degree in Natural Sciences
 - Organisation: Major in Pharmacology University of Stockholm & Karolinska Institutet, Stockholm
 - Country: Sweden

Additional information

Publications

Radresa O, Dahllöf H, Nyman E, Nolting A, Alberta JS and Raboisson P. Roles of TRPA1 in Pain Pathophysiology and Implications for the Development of a New Class of Analgesic Drugs. *The Open Pain Journal*, 2013, 6, (Suppl1 M14) 137_153. Raboisson P, Breitholtz_Emanuelsson A, Dahllöf H, Edwards L, Heaton WL, Isaac M, Jarvie K, Kers A, Minidis AB, Nordmark A, Sheehan SM, Slassi A, Ström P, Terelius Y, Wensbo D, Wilson JM, Xin T, McLeod DA. Discovery and characterization of AZD9272 and AZD6538_Two novel mGluR5 negative allosteric modulators selected for clinical development. *Bioorg Med Chem Lett*. 2012 22(22):6974_9. Gustafsson* H, Sandin J. Oral pregabalin reverses cold allodynia in two distinct models of peripheral neuropathic pain. *Eur J Pharmacol*. 2009 605(1_3):103_8. * Family name has changed from Gustafsson to Dahllöf Warsame Afrah A, Gustafsson H, Olgart L, Brodin E, Stiller CO, Taylor BK. Capsaicin-evoked substance P release in rat dorsal horn increases after peripheral inflammation: a microdialysis study. *Neurosci Lett*. 2004 368(2):226_30. Stiller CO, Taylor BK, Linderöth B, Gustafsson H, Warsame Afrah A, Brodin E. Microdialysis in pain research. *Adv Drug Deliv Rev*. 2003 55(8):1065_79. Gustafsson H, Flood K, Berge OG, Brodin E, Olgart L, Stiller CO. Gabapentin reverses mechanical allodynia induced by sciatic nerve ischemia and formalin-induced nociception in mice. *Exp Neurol*. 2003 182(2):427_34. Kjörsvik Bertelsen A, Warsame Afrah A, Gustafsson H, Tjølsen A, Hole K, Stiller CO. Stimulation of spinal 5-HT(2A/2C) receptors potentiates the capsaicin-induced in vivo release of substance P-like immunoreactivity in the rat dorsal horn. *Brain Res*. 2003 987(1):10_6. Afrah AW, Fiskå A, Gjerstad J, Gustafsson H, Tjølsen A, Olgart L, Stiller CO, Hole K, Brodin E. Spinal substance P release in vivo during the induction of long-term potentiation in dorsal horn

neurons. Pain 2002 96(1_2):49_55. Afrah AW, Gustafsson H, Olgart L, Brodin E, Stiller CO. Changes in spinal cholecystokinin release after peripheral axotomy. Neuroreport. 2001 12(1):49_52. Afrah AW, Stiller CO, Olgart L, Brodin E, Gustafsson H. Involvement of spinal N_methyl_D_aspartate receptors in capsaicin_induced in vivo release of substance P in the rat dorsal horn. Neurosci Lett. 2001 316(2):83_6. Gustafsson H, Afrah AW, Stiller CO. Morphine_induced in vivo release of spinal cholecystokinin is mediated by delta_opioid receptor effect of peripheral axotomy. J Neurochem. 2001 78(1):55_63. Gustafsson H, Stiller CO, Brodin E. Peripheral axotomy increases cholecystokinin release in the rat anterior cingulate cortex. Neuroreport. 2000 11(15):3345_8. Calcutt NA, Stiller C, Gustafsson H, Malmberg AB. Elevated substance_P_like immunoreactivity levels in spinal dialysates during the formalin test in normal and diabetic rats. Brain Res. 2000 856(1_2):20_7. Gustafsson H, de Araujo Lucas G, Schött E, Stiller CO, Alster P, Wiesenfeld_Hallin Z, Brodin E. Measurement of cholecystokinin release in vivo in the rat spinal dorsal horn. Brain Res Protoc. 1999 4(2):192_200. Gustafsson H, Afrah A, Brodin E, Stiller CO. Pharmacological characterization of morphine_induced in vivo release of cholecystokinin in rat dorsal horn: effects of ion channel blockers. J Neurochem. 1999 73(3):1145_54. Gustafsson H, de Araujo Lucas G, Schött E, Stiller CO, Alster P, Wiesenfeld_Hallin Z, Brodin E. Peripheral axotomy influences the in vivo release of cholecystokinin in the spinal cord dorsal horn_possible involvement of cholecystokinin_B receptors. Brain Res. 1998 790(1_2):141_50. Stiller CO, Gustafsson H, Fried K, Brodin E. Opioid_induced release of neurotensin in the periaqueductal gray matter of freely moving rats. Brain Res. 1997 774(1_2):149_58. D'Haese JG, D'Haese TD, Sezgin H, Bergmann F, Teller S, Kehl T, Demir IE, Dahllöf H, Sandberg K, Mayerle J, Friess H, Ceyhan GO. Disruption of the fractalkine/CX3CR1 axis attenuates acute pancreatitis and pancreatic pain, submitted 2015 * Family name has changed from Gustafsson to Dahllöf

Projects

Experimental pain research

Memberships

Participation in Scientific Conferences: SFN, Society for Neuroscience 27th annual meeting, New Orleans, 1997 SFN, Society for Neuroscience 28th annual meeting, Los Angeles, 1998 INRC, International Narcotics Research Conference (INRC) annual meeting, Saratoga Springs, New York, 1999 IASP, 9th World Congress on Pain, Vienna, 1999 SFN, Society for Neuroscience 31st annual meeting, San Diego, 2001 SFN, Society for Neuroscience 33rd annual meeting, New Orleans, 2003 Spring Pain Research Conference, Cayman Island Spring Pain Research Conference, Cayman Island, 2002 & 2004 SFN, Society for Neuroscience 34th annual meeting, San Diego, 2004 SFN, Society for Neuroscience 35th annual meeting, Washington DC, 2005 SFN, Society for Neuroscience 36th annual meeting, Atlanta, 2006 SFN, Society for Neuroscience 37th annual meeting, San Diego 2007 IASP, 12th World Congress on Pain, Glasgow, 2008 IASP, 13th World Congress on Pain, Montreal, 2010 SFN, Society for Neuroscience 41st annual meeting, Washington 2011 SFN, Society for Neuroscience 43rd annual meeting, San Diego 2013 IASP, 15th World Congress on Pain, Buenos Aires. 2014

Other Relevant Information